[Involvement of TAP2 and LMP7 gene polymorphisms in HCV infection].
We aimed to study whether TAP and LMP polymorphisms could influence the severity of liver disease or the response to IFN treatment in patients with chronic HCV infection. TAPZ*0103 gene frequencies in carriers with normal ALT was significantly higher than that in CLD patients. As for the results of IFN responses, LMP7-K gene frequency in sustained-responders was higher than that in non-responders. Multivariate analysis revealed that LMP7-K and HCV RNA quantity were independent factors influencing the outcome of IFN therapy. Furthermore, among patients with a low viral load, the LMP7-K positive patients had a significantly higher ratio of sustained response compared to those without LMP7-K. The TAP2 polymorphism may be closely associated with low hepatitis activity, whereas the LMP7 polymorphism influences the efficacy of IFN treatment and can be a useful predictive parameter in HCV patients with a low viral load.
Kuzushita
N
N
Department of Molecular Therapeutics, Osaka University Graduate School of Medicine.
Sugimoto
Y
Y
Sasaki
Y
Y
Hayashi
N
N
D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters / Q000235:genetics*; D003546:Cysteine Endopeptidases; D006680:HLA Antigens / Q000235:genetics; D006239:Haplotypes; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D009097:Multienzyme Complexes; D011110:Polymorphism, Genetic; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000235:genetics*; D016896:Treatment Outcome
D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters; D006680:HLA Antigens; D009097:Multienzyme Complexes; D011506:Proteins; C071692:TAP2 protein, human; D007372:Interferons; D003546:Cysteine Endopeptidases; C077436:LMP7 protein; D046988:Proteasome Endopeptidase Complex